120 related articles for article (PubMed ID: 37003074)
1. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract][Full Text] [Related]
2. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
3. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
4. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
5. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Toboni MD; Wu S; Farrell A; Xiu J; Ribeiro JR; Oberley MJ; Arend R; Erickson BK; Herzog TJ; Thaker PH; Powell MA
Gynecol Oncol; 2023 Oct; 177():132-141. PubMed ID: 37683549
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
9. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
[TBL] [Abstract][Full Text] [Related]
10. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
11. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
12. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
13. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
14. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract][Full Text] [Related]
15. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
16. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract][Full Text] [Related]
19. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
